These authors contributed equally to the work Glucocorticoids are effective inhibitors of epidermal proliferation and skin tumorigenesis. Glucocorticoids affect cellular functions via glucocorticoid receptor (GR), a well-known transcription factor. Recently, we generated skin-targeted transgenic mice overexpressing GR under control of the keratin5 promoter (K5-GR mice). To test the hypothesis that GR plays a role as a tumor suppressor in skin, we bred K5-GR transgenic mice with Tg.AC transgenic mice, which express v-Ha-ras oncogene in the skin, and compared the susceptibility of F1 offspring to TPA-induced skin carcinogenesis. GR overexpression in the epidermis dramatically inhibited skin tumor development. In K5-GR/ras+ double transgenic mice papillomas developed later and the average number of tumors per animal was 15% (in males) and 40% (in females) of the number seen in wild type (w.t./ras+) littermates. In addition, the papillomas in w.t./ras+ animals were eight to nine times larger. GR overexpression resulted in a decrease in keratinocyte proliferation combined with a modest increase in apoptosis and differentiation of keratinocytes in K5-GR/ras+ papillomas. Our data clearly indicate that interference of GR transgenic protein with nuclear factor kappa B (NF-jB) transcription factor had resulted in NF-jB blockage in K5-GR/ras+ tumors. We discuss the role of NF-jB blockage in tumor-suppressor effect of GR.
Introduction
The glucocorticoid hormones are potent inhibitors of epidermal proliferation and effective inhibitors of mouse skin tumorigenesis, especially during the promotion stage of carcinogenesis when applied to the skin together with different tumor promoters (Schwarz et al., 1977; Verma et al., 1983; Slaga, 1984; DiGiovanni et al., 1988) . The glucocorticoid control of cellular functions is mediated via the glucocorticoid receptor (GR), a wellknown transcription factor (Beato et al., 1995) . Unliganded GR resides in the cytosol associated with a heat-shock protein complex. Following hormone binding, GR dissociates from the complex and migrates as a homodimer to the nucleus, where it binds to glucocorticoid-response elements (GRE) in gene promoters (Beato et al., 1995) . GR acts via two different mechanisms: transcriptional regulation that requires DNA-binding and protein-protein interaction between GR and other transcription factors, such as nuclear factor kappa B (NF-kB) or AP-1, which is independent of DNAbinding (Adcock, 2001) . Experiments with transgenic mice harboring mutated GR which cannot activate GRE containing promoters clearly indicated that many important effects of glucocorticoids including their antiinflammatory effect and blockage of TPA-induced response in skin depend on GR interaction with NFkB and AP-1 (Tuckermann et al., 1999; Reichardt et al., 2001) .
In striking contrast to normal keratinocytes, transformed keratinocytes become resistant to the growth inhibition by glucocorticoids both in vitro and in vivo. We found previously that GR function is dramatically altered in mouse transformed keratinocytes Spiegelman et al., 1997) . As a consequence, glucocorticoid hormones did not affect the growth of established papillomas nor their conversion to carcinomas (Schwarz et al., 1977; Hennings, 1987; Strawhecker and Pelling, 1992; Budunova et al., 1997) . Based on these data, we hypothesized that GR acts as a tumor suppressor in skin and that the resistance to glucocorticoids appears to be an important mechanism of skin tumorigenesis.
To study the impact of both DNA-dependent and -independent mechanisms of GR action on skin tumor development, we used skin-specific GR transgenic animals in which keratin5 promoter drives the GR expression to basal keratinocytes and keratinocytes in the outer root sheath of hair follicles (K5-GR mice) (Perez et al., 2001) . We previously reported that K5-GR animals are much less sensitive to the induction of epidermal hyperplasia by a tumor promoter such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (Perez et al., 2001) . Based on the strong correlation between the ability of tumor promoters to induce sustained skin hyperplasia and their tumor-promoting activities (Slaga et al., 1996) , one would expect that K5-GR transgenic mice would be very resistant to tumor development.
K5-GR transgenic mice were originally generated in F1 C57B1 Â DBA (B6D2) genetic background. It is known that C57B1 mice are highly resistant to skin carcinogenesis (Nesnow et al., 1986; Fischer et al., 1989) . C57B1 Â DBA mice appeared to be more sensitive to skin carcinogenesis than C57B1 mice (Naito et al., 1988; DiGiovanni et al., 1992) . However, while most of C57B1 Â DBA mice do develop tumors in two-stage skin carcinogenesis protocol, the average number of tumors per animal was very low (DiGiovanni et al., 1992) . Thus, to successfully test our hypothesis that GR plays a role of tumor-suppressor gene, we had to use a mouse model that develops numerous skin tumors. To this end, we bred K5-GR transgenic mice with Tg.AC transgenic mice, which express the v-Ha-ras oncogene (Spalding et al., 1993; Thompson et al., 1998) . When treated with TPA, Tg.AC mice rapidly develop multiple skin papillomas (Spalding et al., 1993) . Given that point mutations in mouse Ha-ras oncogene occur in 90% of skin tumors induced by 7,12-dimethylbenz[a]-anthracene (DMBA) (Binder et al., 1998) , introduction of v-Ha-ras transgene into genetically engineered mice is a widely used approach to study their susceptibility to skin carcinogenesis (Larcher et al., 1998; Robles et al., 1998; Smith et al., 1998) . We report here that GR overexpression in the epidermis dramatically inhibited skin tumor development induced by oncogenic ras.
Results

GR overexpression in the epidermis inhibited skin tumorigenesis
To study the effect of GR on skin tumor development, we used F1 offspring of B6D2 hemizygous K5-GR transgenic males (Perez et al., 2001) and FVB females that contained v-Ha-ras transgene under the control of inducible z-globin promoter (Tg.AC mice). Since v-Haras transgene induction by TPA and consequently, skin tumor development are strongly age-dependent (Battalora et al., 2001), we used 12-14-week-old mice. Overall, we used 37 K5-GR/ras+ double transgenic animals (18 females and 19 males) and 46 w.t./ras+ littermates (25 females and 21 males) for tumor experiments.
The results of susceptibility of K5-GR/ras+ and w.t./ ras+ to skin tumor promotion are summarized in Figure 1 . Males of both genotypes appeared to be more resistant to skin carcinogenesis than females (Figure 1a and b). During first 10 weeks of TPA treatment, the percent of animals with tumors and the average number of tumors per mouse were significantly lower in male groups (P ¼ 0.005 for tumor counts) in comparison with the corresponding female groups.
Both male and female transgenic mice with GR overexpression appeared to be more resistant to the induction of papillomas by TPA. In K5-GR/ras+ mice, first papillomas developed 1-2 weeks later ( Figure 1a and b) than in w.t./ras+ animals. The number of animals with papillomas in K5-GR/ras+ transgenics was significantly lower than in w.t./ras+ mice. Interestingly, the percent of animals with more than one tumor was significantly greater in w.t./ras+ males than in K5-GR/ras+ males throughout all the period of TPA treatment (95 versus 31.6% at 15 weeks of the study). The percent of female mice with more than one tumor was significantly greater in w.t./ras+ group only through week 10 of TPA treatment (91 versus 61% at 10 weeks of treatment). These results suggest that there is a higher efficacy of GR as a skin tumor suppressor in male mice.
The average number of tumors per animal in K5-GR/ ras+ mice was 8-22% of the number seen in w.t./ras+ male and female littermates at 10 weeks of TPA treatment (Po0.0001 for both sexes), and 15-40% of the number seen in w.t./ras+ male and female littermates at 15 weeks of TPA treatment (Po0.001 for both sexes). In addition, the papilloma volumes in w.t./ras+ littermates were eight to nine times larger than tumor volumes in K5-GR/ras+ double transgenic mice (Po0.001) ( Figure 1c ). Thus, despite the different dynamics of skin tumor development in males and females, GR overexpression caused a large reduction in sensitivity to skin carcinogenesis in animals of both sexes.
The morphology of the epithelial component of the papillomas that developed in K5-GR/ras+ double transgenic mice was, in general, typical for these types of tumors. However, the basal layer of keratinocytes in the tumors as well as in surrounding skin from K5-GR transgenic animals was disorganized ( Figure 4 and data not shown), and many hair follicles in K5-GR skin surrounding tumors were dysplastic (data not shown). We also found frequent changes in the stromal component of K5-GR/ras+ tumors, including increased overall cellularity, infiltration with polymorphonuclear leukocytes and abnormally dilated blood vessels ( Figure 4 and data not shown).
Transgene expression
We analysed GR protein levels in K5-GR/ras+ and w.t./ras+ mice by Western blotting and immunostaining. GR levels were significantly higher in K5-GR/ras+ tissues ( Figure 2a ). Immunostaining revealed that GR had nuclear localization in basal and some suprabasal keratinocytes in skin (data not shown) and tumors ( Figure 2b ) of K5-GR/ras+ mice. In contrast, GR was exclusively cytoplasmic in keratinocytes in papillomas of w.t./ras+ littermates ( Figure 2b ). To evaluate the function of GR in transgenic tissues, we examined the mRNA levels of the glucocorticoid-responsive gene metallothionein 1 (Mt1) , Spiegelman et al., 1997 . Northern blot analysis revealed the " Figure 2 Expression and activity of GR in tumors and surrounding skin from K5-GR/ras+ and w.t./ras+ animals. Skin papillomas and surrounding skin (SS) at 15 weeks of TPA treatment were used. Representative samples from the tissues of two different animals (one male, one female) are shown for each group. Genetic background is indicated. (Figure 2c ). This strongly suggests that GR is constitutively active in keratinocytes of K5-GR transgenics.
It has been reported that Tg.AC mice do not express v-Ha-ras transgene in nontumor-bearing skin because of the hypermethylation of z-globin promoter (Cannon et al., 1998) . Chronic treatment with TPA leads to the hypomethylation of transgene promoter concomitant with the v-Ha-ras mRNA and protein expression, which are significantly higher in preneoplastic lesions and in papillomas than in surrounding skin (Hansen and Tennant, 1994) . Data presented in Figure 3 clearly indicate that GR overexpression did not affect the expression of v-Ha-ras transgene during skin tumor development after TPA treatment. Indeed, Southern blot analysis with two restriction enzymes (methylationsensitive MspI and methylation-insensitive HpaII) showed that z-globin promoter was hypomethylated in both GR transgenic and w.t. skin papillomas (Figure 3a) , which resulted in v-Ha-ras activation and equally strong expression in tumors of both genotypes as compared to surrounding skin (Figure 3b and c) .
Effect of GR overexpression on keratinocyte proliferation, differentiation and apoptosis
The dramatic reduction in tumor size strongly suggest that GR overexpression in transformed keratinocytes results in an altered balance between proliferation and differentiation (or apoptosis) in K5-GR/ras+ papillomas. It is known that glucocorticoids inhibit proliferation in several different cell types including normal keratinocytes in vivo and in vitro. We compared the number of bromodeoxyuridine (BrdU)-positive cells in K5-GR/ras+ and w.t./ras+ papillomas and the surrounding skin. As shown in Figure 4 , GR overexpression resulted in a 30% inhibition of proliferation in tumors. These data are in line with our previous observation that GR overexpression significantly inhibits the proliferative response of keratinocytes to acute TPA treatment in K5-GR transgenic mice (Perez et al., 2001) .
Glucocorticoids induce G1 cell cycle arrest in some cell types through the activation of cyclin-dependent kinase (CDK) inhibitors p21/Cip1 and p27/Kip1 (Rogatsky et al., 1997; Cha et al., 1998; Rogatsky et al., 1999; Samuelsson et al., 1999; Park et al, 2001; Terada et al, 2001 ). Thus, we analysed whether GR affected the expression of p21 and p27 CDK inhibitors, as well as cyclin D1, which is usually overexpressed in skin papillomas (Robles and Conti, 1995) . To our surprise, GR overexpression did not alter the protein levels of cyclin D1, p21 and p27 ( Figure 5 ).
Since glucocorticoid hormones and GR itself have been shown to induce apoptosis in some cell types (Jehn and Osborne, 1997; Distelhorst, 2002; Greenstein et al., 2002) , we examined tumor sections for apoptotic cells by the terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay. As shown in Figure 6 , we found only a modest increase in the number of apoptotic keratinocytes in differentiated compartments of K5-GR/ras+ papillomas in comparison with w.t./ras+ papillomas. Immunostaining did not show a significant difference in either abundance or localization of keratin 1 and loricrin proteins in K5-GR/ras+ and w.t./ras+ tumors (data not shown). However, in some areas of K5-GR/ras+ tumors, the immunostaining revealed more layers of keratin 1-and loricrin-positive suprabasal keratinocytes than in w.t./ras+ tumors, suggesting an increase in keratinocyte differentiation.
Effect of GR overexpression on NF-kB
It is known that GR interaction with NF-kB leads to a functional inhibition of NF-kB (Scheinman et al., 1995; Adcock, 2001) . Our earlier work revealed that GR overexpression dramatically reduced NF-kB binding activity and expression of kB-responsive genes in skin of K5-GR transgenic mice (Perez et al., 2001) . We also showed that NF-kB is constitutively activated in mouse skin tumors induced by the DMBA/TPA protocol, partially because of a strong increase in p50 (NF-kB1) expression and a decrease in the steady-state level of IkBa inhibitor in comparison with untreated epidermis (Budunova et al., 1999) . Therefore, we evaluated the NF-kB status in K5-GR/ras+ and w.t./ras+ tumors.
NF-kB binding activity was analysed by electrophoretic mobility shift assay (EMSA) using nuclear protein extracts from skin tumors and untreated skin of w.t./ras+ animals. As we expected, GR overexpression dramatically inhibited kB binding in skin tumors (Figure 7b ). Western blot analysis did not reveal changes in p50, p65 or IkBa expression in K5-GR/ ras+ tumors in comparison to w.t./ras+ tumors (Figure 7a ). This suggests that inhibition of NF-kB Effect of GR on the expression of cell cycle-related proteins. Western blots containing whole-cell protein extracts (20 mg/lane) from mouse skin tumors at 15 weeks of TPA treatment were probed for expression of cyclin Dl, p21 and p27. Representative samples from the tissues of two different animals (one male, one female) are shown for each group. Genetic background is indicated occurs at the functional level but not through the regulation of NF-kB/IkB (inhibitory proteins of NF-kB) expression levels by activated GR.
Discussion
Using skin-specific GR transgenic animals, we have provided evidence of the tumor-suppressor role of GR in skin carcinogenesis. The constitutive nuclear overexpression and activation of GR in the epidermis dramatically inhibited skin tumor development in K5-GR/ras+ double transgenic mice in terms of number of animals that developed tumors, number of papillomas per animal and tumor size. Since GR mediates the effect of glucocorticoid hormones, our results are in line with previous findings that glucocorticoids are very potent inhibitors of skin tumor formation (Schwarz et al., 1977; Verma et al., 1983; Slaga, 1984; DiGiovanni et al., 1988) .
The large reduction in the number of papillomas suggests that GR overexpression affected either the number of target cells in transgenic skin or their sensitivity to ras-induced transformation. Epidermal stem cells that reside in a specific area of hair follicles were hypothesized to be target cells for skin carcinogenesis (Morris, 2000) . We revealed that there was 25% reduction in the number of hair follicles in dorsal skin of K5-GR/ras+ transgenics (data not shown). Thus, this decrease in the number of hair follicles in animals with GR overexpression cannot account for the drastic reduction in the tumor number in those mice.
We found earlier that TPA effect on the expression of certain genes was abolished in K5-GR transgenic mice (Perez et al., 2001) . These results suggest that activation of v-Ha-ras transgene by TPA may be less effective in keratinocytes of K5-GR/ras+ mice. Further, the induction of ras-signaling pathway by several growth factors and by tumor promoters such as TPA leads to NF-kB activation. Since downstream NFkB activation appears to be necessary for ras-induced transformation of different cell types (Finco et al., 1997; Mayo et al., 1997; Jo et al., 2000) , we hypothesized that blockage of NF-kB in the skin of K5-GR transgenic animals (Perez et al., 2001) represents an important mechanism for the resistance to v-Ha-ras-induced transformation. Figure 6 Effect of GR overexpression on keratinocyte apoptosis in mouse skin papillomas. The level of apoptosis was measured in papillomas of K5-GR/ras+ and w.t./ras+ animals at 15 weeks of TPA treatment by TUNEL immunostaining. Note the increased number of apoptotic keratinocytes in K5-GR/ras+ papilloma Figure 7 Effect of GR overexpression on NF-kB status in mouse skin papillomas. Skin papillomas at 15 weeks of TPA treatment and untreated skin (S) from w.t./ras+ animals were used. Representative samples from the tissues of two different animals (one male, one female) are shown for each group. Genetic background is indicated. (a) Western blot analysis of NF-kB and IkBa expression in mouse papillomas. Western blots containing whole-cell protein extracts (20 mg/lane) from mouse tissues were probed for the expression of NF-kB1 (p50), RelA (p65) and IkBa. (b) EMSA analysis of kB binding. Nuclear proteins (10 mg/reaction) from tissues were used for EMSA The reduction of tumor size in K5-GR/ras+ animals appears to be related to inhibition of keratinocyte proliferation induced by oncogenic ras. CDK inhibitors p21 and p27, as well as cyclin D1 are well known targets for ras (Pruitt and Der, 2001; Takuwa and Takuwa, 2001) . Cyclin D1 mediates the proliferative response to ras in the skin and is a critical target for the activated ras in mouse skin carcinogenesis (Robles et al., 1998) . Moreover, TPA-induced skin tumorigenesis was significantly reduced when v-Ha-ras transgene was transferred to cyclin D1-deficient genetic background (Robles et al., 1998) . Glucocorticoids or GR overexpression have been reported to induce a G1 cell cycle arrest via an increased expression of p21 that has GRE in its promoter (Ramalingam et al., 1997; Rogatsky et al., 1997 Rogatsky et al., , 1999 Cha et al., 1998; Park et al., 2001; Terada et al., 2001) . The alternative mechanism may involve the transcriptional repression of kB-dependent cyclin D1 (Guttridge et al., 1999) . Surprisingly, we have not revealed changes in the level of p21, p27 and cyclin D1 in K5-GR/ras+ skin tumors. Thus, our data suggest that the antiproliferative effect of GR in keratinocytes may be mediated through other G1/S phase-related target molecules, such as CDK4, CDK6, CDK2, CyclinD3 or CyclinA, whose expression is regulated by glucocorticoids/GR in some other cell types (Rogatsky et al., 1997; Smith et al., 2000) .
We also investigated whether GR overexpression could induce a significant level of apoptosis in K5-GR transformed keratinocytes, as reported for some other cell types (Jehn and Osborne, 1997; Greenstein et al., 2002; Distelhorst, 2002) . In this context, it is important that NF-kB is a key antiapoptotic factor (Barkett and Gilmore, 1999) , and activation of ras in combination with NF-kB blockage resulted in an increased level of apoptosis in certain cells (Mayo et al., 1997 (Mayo et al., , 2001 Nalca et al., 1999) . Surprisingly, in our experiments, we found only a modest increase in apoptosis in keratinocytes in the upper granular layer of K5-GR+/ras+ tumors in comparison with w.t./ras+ tumors. GR overexpression slightly increased the expression of intermediate/late keratinocyte differentiation markers such as keratin 1 and loricrin. Altogether, the reduction of tumor size in K5-GR+/ras+ transgenic animals seems to be the result of inhibited proliferation combined with some increase in apoptosis and differentiation in transformed keratinocytes that overexpress GR.
In summary, our results provide for the first time in vivo evidences that GR plays a tumor-suppressor role in skin carcinogenesis induced by oncogenic ras, possibly through transrepression of NF-kB-dependent genes and alteration of proliferation/apoptosis/differentiation balance in transformed keratinocytes. Our studies indicate that GR activation in keratinocytes did not exert usual changes in the expression of cell cyclerelated proteins. Further investigation of the crosstalk between GR, ras and NF-kB will lead to a better understanding of their role in skin function and tumorigenesis.
Materials and methods
Animals and skin tumor experiment
Hemizygous female Tg.AC mice were purchased from Taconic Farms, Inc. (Germantown, NY, USA). K5-GR hemizygous mice of line 285 (B6D2 genetic background) were previously described (Perez et al., 2001) . For tumor experiments, we used F1 offspring (FVB : B6D2 1 : 1 background) harboring v-Haras transgene alone (w.t./ras+ mice) or both transgenes v-Haras and GR (K5-GR/ras+ mice). The tumor experiment was performed in three phases owing to the large deviation in the date of birth of transgenic animals. At 12-14 weeks of age, mouse dorsal skin was shaved and 2 days later treated topically twice a week with 5 mg TPA/animal in 200 m1 of acetone during 15 weeks, followed by a 1-week recovery period prior to necropsy. The incidence of papillomas in the shaved area was recorded weekly. To prevent wound-related skin tumor development previously reported for Tg.AC mice (Cannon et al., 1997) , males were housed individually during TPA treatment.
Statistical analysis
First, the data were analysed for differences in the effect of sex as well as phase of tumor experiment. Males of both genetic backgrounds appeared to be more resistant to the tumor development than females. Thus, we analysed and presented data for both sexes separately. Since the results of three phases of tumor experiment were not statistically different, the data obtained in those experiments were combined. Tumor multiplicity data were assessed using Poisson's regression. Tumor incidence (defined as percent of animals with more than one tumor) in w.t./ras+ and K5-GR/ras+ groups was analysed using a w 2 test for independent proportions. Owing to a large tumor burden, animals with large or numerous tumors were killed before 15 weeks of treatment. Thus, for statistical tests of multiplicity at 15 weeks of treatment, we used last value carried forward (LVCF) for animals killed after week 10. Differences in tumor size in w.t./ras+ and K5-GR/ras+ animals were assessed using a two-group median test. Tumors were harvested at 15 weeks of promotion from five mice of each genetic background, and tumor volumes were calculated by multiplying the three largest diameters of each tumor.
Southern blotting
For animal genotyping, mouse tail DNA (5 mg) was digested with BamHI (v-Ha-ras transgene genotyping) or EcoRI (GR transgene genotyping) and subjected to electrophoresis. Southern blots were probed by using random primed 32 P-labeled probes. Specific keratin 5 probe (Perez et al., 2001) and PCRamplified fragment of the z-globin promoter were used for GR and H-v-ras transgene genotyping, respectively. Since some Tg.AC mice lose transgene (Honchel et al., 2001) , the probe for z-globin promoter was designed to recognize specifically Tg.AC mice with functional transgene (Cannon et al., 1998) . The template and primers were a kind gift from Dr R Cannon (NIEHS, Research Triangle Park, NC, USA).
z-Globin promoter methylation
The methylation status of z-globin promoter was evaluated by Southern blot analysis using DNA isolated from tumors and surrounding skin digested with HpaII (methylation-independent) or MspI (methylation-sensitive) endonucleases, and PCR-amplified fragment of the z-globin promoter as a probe.
Immunostaining for GR and keratinocyte differentiation markers
Formalin-fixed sections were deparaffinized, blocked with 1% of bovine serum albumin, incubated with primary antibodies, and immunostaining was visualized with the avidin-biotin Complex (ABC) kit (Vectastain Elite, Vector Laboratories, Inc., Burlingame, CA, USA) as previously described (Pe´rez et al., 2001) . Polyclonal antibody against GR was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), polyclonal antibodies against keratin 1 and loricrin were from Covance Inc. (Princeton, NJ, USA).
BrdU staining
BrdU (6 mg/kg of body weight) was injected intraperitoneally 1 h before the animals were killed. Tumors and surrounding skin were fixed in methacarn (60% methanol, 30% chloroform and 10% glacial acetic acid) and immunostaining was performed as previously described (Pe´rez et al., 2001) . Monoclonal anti-BrdU antibody was from Becton Dickinson (Mountain View, CA, USA). Sections were counterstained with hematoxylin, and the number of BrdU-positive keratinocytes was calculated as percentage of 500 basal cells counted per slide in five samples of tumors and in five samples of surrounding skin from different animals of each genetic background.
Apoptosis detection
The TUNEL assay was performed on formalin-fixed, paraffinembedded tumor sections by using the Apoptag kit (Serologicals Corporation, Norcross, GA, USA) according to the manufacturer's protocol.
Western blotting
Whole-cell protein extracts were prepared as previously described (Budunova et al., 1999) , separated by SDS-PAGE and transferred to Immobilon-P membrane (Millipore Corporation, Bedford, MA, USA). Membranes were stained with Ponceau S to verify equal protein loading and transfer. Bands were visualized using Amersham ECL Hyperfilm. The antibodies against p50 (NF-kB1), p65 (RelA), IkBa, cyclin D1, p21, p27, GR and Ha-ras were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Northern Blotting
Total RNA was isolated from tumors and surrounding skin ground in liquid nitrogen using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH, USA). Northern blots (20 mg/lane) were probed for expression of v-Ha-ras and Mt1. DNA probes were labeled by random primed reactions (RediprimetII, Amersham, Piscataway, NJ, USA) using the complete coding sequences of v-Ha-ras murine sarcoma virus oncogene (ATCC, Manassas, VA, USA) and murine Mt1 (kind gift from Dr R Lebovitz, Baylor College of Medicine, Houston, TX, USA) as templates.
EMSA
EMSA was performed by incubating nuclear extracts from mouse skin tumors and surrounding skin with a labeled oligonucleotide corresponding to a palindromic kB site as previously described (Perez et al., 2000) . Complexes were separated on 5.5% native polyacrylamide gels in 0.25 Â Trisborate-EDTA buffer, dried and exposed to Hyperfilm-MP (Amersham) at À701C. Abbreviations B6D2, F1 C57B1 Â DBA mice; BrdU, bromodeoxyuridine; CDK, cyclin-dependent kinase; DMBA, 7,12-dimethylbenz[a]-anthracene; GR, glucocorticoid receptor; GRE, glucocorticoid response element; IkB, inhibitory proteins of NF-kB; Mt1, metallothionein 1; NF-kB, nuclear factor kappa B; TPA, 12-O-tetradecanoyl-phorbol-13-acetate.
